On September 16, 2004, Constan, Alexander Angelo; Keshary, Prakash Raj; MacLean, David Burton; Paralkar, Vishwas Madhav; Roman, Doina Cosma; Thompson, David Duane; Wright, Timothy Michael published a patent.Recommanded Product: 142327-44-4 The title of the patent was Use of EP2 selective receptor agonists in medical treatment of pulmonary hypertension and other conditions. And the patent contained the following:
The invention discloses methods for treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist. Preparation of compounds, e.g. 7-[(4-butylbenzyl)-(pyridine-3-sulfonyl)amino]heptanoic acid, is described. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Recommanded Product: 142327-44-4
The Article related to ep2 receptor agonist therapeutic, pulmonary hypertension treatment ep2 receptor agonist, heptanoate derivative preparation ep2 receptor agonist therapeutic, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Recommanded Product: 142327-44-4
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics